Official UK procurement notice
THE PROVISION OF CLINICAL LABORATORY SERVICES - Molecular Pathology Diagnostic Services (MPDS)
Authority: Maidstone and Tunbridge Wells NHS Trust (Central government)
Molecular testing service. Description of Services: The provision of a testing service for molecular pathology requests and the reporting of these results.
What is being bought
Published requirement descriptionMolecular testing service.
CPV: Services provided by medical laboratories
The lotProcurement structure
single lot · no lot value publishedLot #1Description of Services: The provision of a testing service for molecular pathology…Awarded
Description of Services: The provision of a testing service for molecular pathology requests and the reporting of these results.
Contract Award Statement: Intention to award a contract to an existing provider (University Hospitals Birmingham, Queen Elizabeth Hospital) following Provider Selection Regime direct award process C.
Approximate Lifetime Value of the Contract: £29,379
Contract Period: 1 April 2026 to 31 March 2027
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| University Hospitals Birmingham NHS FT Queen Elizabeth Hospital Birmingham | £29,379 † | — | Awarded |
Contracts
Contract 102799-2026-1 · University Hospitals Birmingham NHS FT Queen Elizabeth Hospital Birmingham
- Signed
- 1 Oct 2026
- Value
- £29,379
- Status
- active
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 1bids | — | — | — |
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Services
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Unspecified in notice
- First published
- 29 Oct 2026, 15:54 GMT
- Last source update
- 29 Oct 2026, 15:54 GMT
- Authority reference
518- FTS notice number
2026/S 000-102799- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-0793ecFind a Tender
- Why no open competition
- The procurement falls outside the scope of application of the directive
- Published justification
This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by midnight on 10th November. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.
Publisher note: This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by midnight 10 November 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR. Address for written representations: [email protected] Award Decision makers: Maidstone and Tunbridge Wells NHS Trust's Head of Service - Pathology and Molecular Pathology Lead BMS supported by Income and Contracts team and Finance Manager. Conflicts of Interest: There were no conflicts of interest declared. The Trust operates a Conflicts of Interest policy and procedure. Rational including the relative importance of the key criteria: The Authority intends to directly award a contract to University Hospitals Birmingham NHS FT Molecular Pathology (MPDS) Provided by Queen Elizabeth Hospital under the Direct Award Process C based on the following criteria: Quality and Innovation 25% Conformance with ISO 15189:2022. Established quality systems, digital pathology platforms, specialist expertise and participation in external quality assurance, including the expansion of testing regimes relevant to the treatment of patients. Value 25% Delivering cost-effective services. Communication is a high standard with the additional benefit of clinical advice for complex cases. Integration, collaboration and service sustainability 20% MDT support and specialist referral services. Improving access, reducing health inequalities and facilitating choice 20% Timely access for eligible patients. Social Value 10% Contribution to workforce development, training and research.
Contracting authority & participating public bodies
Dispute resolution & review bodies
- PSR Review PanelReview body
Bidders & participating suppliers
1 commercial party on the noticeOfficial documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.